idiopath
subglott
stenosi
isg
debilit
extrathorac
obstruct
involv
lower
laryng
upper
tracheal
airway
aris
without
known
anteced
injuri
associ
diseas
emerg
studi
demonstr
affect
patient
possess
tightli
conserv
clinic
histopatholog
anatom
physiolog
despit
descript
isg
four
decad
recent
inflammatori
fibros
phenotyp
character
molecular
level
data
show
highli
upregul
activ
inflammatori
pathway
mucos
scar
isg
yet
mechan
respons
characterist
demarc
airway
inflamm
unknown
altern
pulmonari
structur
function
chang
lung
epithelium
appear
integr
fibrot
remodel
occur
set
chronic
airway
inflamm
epitheli
microbiota
dysbiosi
subsequ
sustain
host
inflamm
found
chronic
inflammatori
mucos
although
trachea
line
respiratori
epithelia
readili
support
colon
divers
microbiom
upper
respiratori
site
date
noth
known
composit
resid
microbiom
larg
airway
contribut
airway
remodel
idiopath
subglott
stenosi
microbiolog
studi
reli
techniqu
underestim
divers
speci
offer
limit
detect
intracellular
pathogen
applic
approach
offer
opportun
provid
broader
pictur
tracheal
microbiom
composit
identifi
discret
pathogen
speci
associ
diseas
state
previous
work
demonstr
activ
canon
pathway
tracheal
mucosa
isg
patient
identifi
cell
primari
cellular
sourc
given
establish
role
cell
host
defens
mucos
barrier
analyz
tissu
specimen
isg
patient
presenc
microbi
pathogen
unbias
molecular
interrog
tracheal
microbiota
isg
patient
provid
detail
nucleic
acid
protein
immunolog
evid
demonstr
mycobacterium
speci
within
tracheal
scar
togeth
previou
work
studi
offer
new
insight
pathogenesi
isg
suggest
human
tracheal
mucos
health
highli
depend
composit
resid
microbiota
identifi
novel
pathogen
role
establish
larg
airway
bacteria
offer
target
futur
therapeut
intervent
isg
tracheal
stenosi
ilt
normal
control
patient
util
experi
supp
fig
isg
transcript
ilt
diagnosi
confirm
use
previous
describ
clinic
serolog
control
popul
consist
patient
without
known
tracheal
patholog
malign
system
infect
tracheal
scar
freshli
isol
peripher
blood
mononuclear
cell
pbmc
sourc
specimen
isg
ilt
patient
normal
trachea
pbmc
sourc
control
patient
genom
dna
gdna
extract
qiagen
dnaeasi
extract
kit
qiagen
valencia
ca
accord
manufactur
instruct
slight
modif
previous
gdna
concentr
qualiti
confirm
use
bioanalyz
system
agil
santa
clara
ca
human
respiratori
pathogen
quantit
polymeras
chain
reaction
qpcr
array
qiagen
perform
per
manufactur
instruct
steponeplu
instrument
appli
biosystem
foster
citi
ca
express
analysi
perform
use
pcr
array
analysi
softwar
qiagen
isg
ilt
airway
stenosi
tissu
healthi
control
us
biomax
inc
rockvil
md
pretreat
probe
gyras
advanc
cell
diagnost
hayward
ca
follow
modifi
rnascop
assay
hd
detect
kit
red
advanc
cell
diagnost
tissu
digest
dilut
co
llc
st
loui
mo
mm
ph
minut
room
temperatur
experiment
control
run
parallel
includ
bacteri
gene
dapb
neg
control
assess
background
signal
homo
sapien
assess
posit
signal
protocol
efficaci
nest
pcr
analysi
perform
previous
describ
mycobacteri
rpob
condit
primer
list
supplement
data
supp
tabl
neg
posit
control
run
parallel
genom
dna
extract
tuberculosi
strain
serv
posit
control
vircel
technolog
granada
spain
wherea
pcr
master
mix
inocul
steril
water
pcr
master
mix
alon
use
neg
control
rpob
gene
product
run
gel
purifi
bp
band
use
qiagen
qiaquick
gel
extract
kit
qiagen
sequenc
directli
strand
vanderbilt
cancer
center
core
sequenc
laboratori
nashvil
tennesse
align
rpob
sequenc
perform
use
sequench
softwar
gene
code
corpor
ann
arbor
mi
human
tracheal
mucos
biopsi
obtain
oper
room
immedi
fix
chill
buffer
mm
sodium
cacodyl
ph
contain
glutaraldehyd
paraformaldehyd
place
overnight
sampl
prepar
previous
briefli
sampl
block
coldwat
fish
skin
gelatin
mm
sodium
cacodyl
buffer
stain
rabbit
polyclon
tuberculosi
mtb
antibodi
lsbio
inc
seattl
wa
follow
goat
igg
conjug
nm
gold
particl
electron
microscopi
scienc
hatfield
pa
sampl
wash
three
time
phosphat
buffer
salin
contain
tween
analyz
fei
transmiss
electron
microscop
fei
hillsboro
oregon
equip
digit
camera
total
individu
cell
group
imag
analyz
subcellular
architectur
presenc
bacteria
prepar
pbmc
earli
secret
antigen
target
elispot
assay
perform
describ
number
specif
interferon
gamma
secret
cell
calcul
subtract
mean
neg
control
valu
mean
cell
sfc
count
duplic
well
inocul
peptid
neg
control
alway
sfc
per
input
cell
posit
respons
defin
concentr
least
pbmc
least
three
time
higher
background
level
research
assist
blind
clinic
diagnos
studi
particip
throughout
analysi
statist
signific
set
p
valu
less
mean
differ
equal
greater
chang
express
level
normal
distribut
variabl
test
use
test
differ
x
group
determin
use
test
normal
nonnorm
distribut
respect
data
express
median
standard
deviat
nonnorm
distribut
variabl
statist
analys
perform
prism
version
softwar
graphpad
softwar
inc
la
jolla
ca
given
role
cell
host
defens
pathogen
epitheli
mucos
barrier
analyz
tissu
specimen
isg
patient
presenc
microbi
speci
isg
patient
demonstr
pcr
posit
mycobacterium
speci
fig
wherea
two
ilt
patient
posit
pcr
p
contrast
among
ilt
patient
show
pcr
posit
acinetobact
baumannii
establish
icu
wherea
one
isg
patient
show
posit
signal
pathogen
p
confirmatori
test
preform
addit
isg
ilt
healthi
control
situ
hybrid
probe
rna
express
specif
mycobacteri
virul
factor
dna
gyras
subunit
seven
isg
specimen
test
posit
predominantli
tracheal
epithelium
wherea
one
ilt
specimen
healthi
control
sampl
show
detect
signal
p
fig
investig
mycobacterium
speci
within
tracheal
scar
tissu
util
immunogold
label
transmiss
electron
microscopi
analysi
reveal
multipl
structur
associ
label
exhibit
typic
size
shape
coccoid
bacillu
mycobacterium
speci
within
extracellular
matrix
fig
wherea
control
use
secondari
antibodi
alon
data
shown
unrel
antibodi
haemophilu
influenza
fig
neg
digit
quantif
gold
label
per
bacteri
cell
computer
algorithm
confirm
visual
analysi
tuberculosi
complex
mtbc
antibodi
bind
isg
tissu
p
supp
fig
detect
nucleic
amino
acid
signal
mycobacteria
within
isg
sought
assess
system
immunolog
respons
isg
util
elispot
analyz
respons
peripher
leukocyt
isg
patient
mycobacteri
chose
peptid
due
prior
report
system
cellular
immun
respons
conserv
mtbc
virul
factor
peripher
blood
mononuclear
cell
isg
patient
show
mean
sfc
count
standard
error
mean
sem
compar
sem
normal
control
p
fig
respons
suggest
system
immunolog
memori
mtbc
exposur
consist
patholog
role
mtbc
isg
possibl
subtyp
mycobacterium
speci
base
initi
primer
discoveri
assay
therefor
util
sanger
classifi
mycobacterium
speci
subset
sampl
base
rpob
gene
sequenc
rpob
pcr
yield
product
bp
sanger
sequenc
analysi
identifi
mtbc
eight
isg
sampl
seven
eight
posit
isg
specimen
show
consist
polymorph
locat
base
pair
fig
wherea
predict
protein
code
sequenc
isg
specimen
homolog
mtb
refer
sequenc
fig
phylogenet
analysi
amino
acid
sequenc
suggest
rather
mtb
variant
member
mtbc
close
relat
novel
mycobacterium
fig
present
isg
specimen
demonstr
multipl
distinct
approach
presenc
mycobacterium
within
tracheal
scar
isg
patient
prior
find
suggest
major
role
cell
tissu
inflamm
fibrot
remodel
seen
airway
isg
given
establish
role
cell
earli
product
mtbc
critic
role
host
clearanc
pulmonari
mtbc
prior
result
consist
current
work
demonstr
mycobacteri
speci
within
airway
scar
isg
patient
earli
report
describ
isg
clinic
entiti
could
isol
bacteri
routin
microbiolog
cultur
similarli
isg
patient
includ
studi
howev
sinc
public
techniqu
becom
establish
altern
methodolog
identif
infecti
agent
polymeras
chain
reaction
use
identifi
etiolog
agent
bacillari
angiomatosi
bartonella
hensela
whippl
diseas
tropheryma
whippelii
use
immun
respons
microbi
antigen
also
util
identifi
novel
infecti
agent
includ
sin
nombr
viru
hantaviru
pulmonari
well
previous
unknown
coronaviru
sever
acut
respiratori
mycobacterium
peripher
blood
mononuclear
cell
isg
patient
stimul
ex
vivo
mycobacteri
virul
factor
demonstr
pronounc
respons
find
suggest
despit
neg
cultur
result
isg
specimen
mycobacteri
antigen
induc
respons
blood
isg
patient
similar
frequenc
tuberculosi
observ
pronounc
cellular
immun
respons
mycobacterium
antigen
isg
patient
test
strongli
support
result
molecular
protein
analysi
isg
scar
inabl
identifi
mycobacteri
microorgan
routin
histolog
stain
cultur
microorgan
patholog
tissu
provid
caution
establish
caus
role
infecti
agent
isg
pathogenesi
howev
base
prior
microbiolog
experi
fastidi
mycobacteria
sever
explan
failur
detect
microbi
speci
isg
initi
report
diseas
bacteria
may
present
quantiti
detect
histolog
altern
agent
may
ultraslow
growth
pattern
necessit
incub
period
much
longer
standard
week
cultur
held
isol
mycobacterium
tuberculosi
similar
time
need
isol
convers
isg
pathogenesi
may
reflect
immun
respons
infecti
antigen
might
depend
activ
replic
organ
similar
hypersensit
pneumon
induc
mycobacterium
associ
mycobacterium
isg
immunopathogenesi
support
detect
mycobacteri
protein
nucleic
acid
isg
scar
well
local
peripher
cellular
immun
respons
mycobacteri
antigen
isg
subject
howev
remain
unresolv
whether
identifi
mycobacteri
constitu
drive
diseas
whether
inflamm
per
se
creat
nich
outgrowth
specif
bacteria
note
howev
tracheal
stenosi
aris
intub
ilt
also
possess
inflammatori
tissu
phenotyp
airway
appear
cohort
much
lower
percentag
patient
detect
mycobacterium
given
diseas
rariti
result
requir
confirm
larger
cohort
pool
multipl
institut
presenc
mycobacterium
within
isg
scar
particularli
strike
light
proven
associ
mycobacterium
otherwis
healthi
older
white
femal
ladi
windermer
syndrom
characterist
patient
women
without
immunocompromis
underli
chronic
lung
diseas
proven
pulmonari
mycobacterium
infect
close
mirror
isg
popul
ladi
windermer
patient
predominantli
caucasian
women
present
dramat
demograph
similar
two
diseas
ntm
pulmonari
infectionladi
windermer
syndrom
isg
offer
clinic
preced
pathogen
role
mycobacterium
develop
progress
isg
although
result
demonstr
mycobacterium
speci
within
tracheal
scar
isg
patient
role
host
genet
isg
pathogenesi
yet
explor
interestingli
strong
altern
evid
link
host
genotyp
mycobacteri
suscept
via
axi
molecular
analysi
patient
suffer
mendelian
suscept
mycobacteri
diseas
implic
polymorph
ligand
receptor
respons
activ
similarli
although
isg
affect
women
nearli
exclus
influenc
estrogen
diseas
initi
recurr
unknown
estrogen
shown
directli
drive
signal
increas
product
sever
role
estrogen
promot
mycobacteri
colonizationinfect
role
acceler
host
respons
pathogen
question
merit
futur
studi
although
isg
long
consid
strictli
anatom
abnorm
requir
surgic
remedi
offer
first
evid
diseas
may
repres
manifest
alter
local
microbi
flora
coupl
patholog
host
inflammatori
respons
demonstr
multipl
distinct
approach
uniqu
associ
mycobacteri
speci
isg
airway
mucosa
togeth
prior
report
demonstr
significantli
upregul
local
evid
mycobacterium
speci
within
tracheal
scar
offer
new
avenu
therapeut
intervent
isg
patient
sever
establish
reagent
avail
inhibit
altern
multipl
drug
avail
target
mycobacterium
speci
interestingli
limit
case
seri
support
clinic
benefit
one
reagent
isg
benefit
inhibit
absenc
pathogen
control
unclear
thu
futur
clinic
trial
could
test
clinic
respons
immunomodul
combin
antibacteri
therapi
therefor
implic
work
may
extend
beyond
confin
isg
diseas
aris
interfac
pathogen
host
inflammatori
respons
ag
design
perform
experi
analyz
data
wrote
articl
nk
analyz
data
mm
design
perform
experi
dn
design
perform
experi
br
aid
experiment
design
jd
ese
e
jk
ah
analyz
data
preform
critic
scientif
review
gg
aid
experiment
design
ly
analyz
data
jr
conduct
experi
jn
aid
experiment
design
cw
aid
experiment
design
df
aid
experiment
design
statist
analysi
cs
conduct
experi
kj
conduct
experi
tm
aid
experiment
design
data
analysi
review
articl
tb
aid
experiment
design
experi
data
analysi
review
articl
jg
conduct
experi
wd
aid
experiment
design
experi
data
analysi
review
articl
